The effect of Treno® medication on the neck scar after thyroidectomy

Clinical trial of double-blind study on scar inhibitory effect and safety of "Treno®" after thyroidectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007956

Enrollment

100

Registered

2022-12-02

Start date

2020-11-30

Completion date

Unknown

Last updated

2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Postoperatively, test drug (tranilast) or placebo (cellactose) 100mg is taken three times a day, daily until postoperative 10 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age between 20 - 70 years 2) Informed and agreed to participate in the clinical trial 3) Expected to receive conventional open thyroidectomy due to thyroid disease

Exclusion criteria

Exclusion criteria: 1) Patients disqualified to enroll based on the researcher's discretion 2) Intake of aspirin or antiplatelet agent within 7 days of hospital admission 3) Patients expected to undertake modified radical neck dissection 4) Patients with previous head and neck radiation therapy 5) Patients with previous neck surgery history 6) Liver diseases, including liver cirrhosis or liver cancer

Design outcomes

Primary

Measure	Time frame
Scar pigmentation, vascularity, pliability, height, and elasticity	—

Secondary

Measure	Time frame
Patient satisfaction, pain, and pruritis regarding surgical scar	—

Countries

Korea, Republic of

Contacts

Public ContactJune Young Choi

Seoul National University Bundang Hospital

juneychoi@snubh.org+82-31-787-7107

Outcome results